Table of Contents
List of Tables
List of Figures
Nanobiotix SA Company Overview
Nanobiotix SA Company Snapshot
Nanobiotix SA Pipeline Products and Ongoing Clinical Trials Overview
Nanobiotix SA – Pipeline Analysis Overview
Nanobiotix SA – Key Facts
Nanobiotix SA – Major Products and Services
Nanobiotix SA Pipeline Products by Development Stage
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA Pipeline Products Overview
Hensify – Breast Cancer
Hensify – Breast Cancer Product Overview
Hensify – Gastrointestinal Cancer
Hensify – Gastrointestinal Cancer Product Overview
Hensify – Genitourinary Cancer
Hensify – Genitourinary Cancer Product Overview
Hensify – Glioblastoma
Hensify – Glioblastoma Product Overview
Hensify – H&N & Lung Cancer
Hensify – H&N & Lung Cancer Product Overview
Hensify – Head & Neck Cancer
Hensify – Head & Neck Cancer Product Overview
Hensify – Head & Neck Cancer Clinical Trial
Hensify – Liver Cancer
Hensify – Liver Cancer Product Overview
Hensify – Liver Cancer Clinical Trial
Hensify – Lung Cancer
Hensify – Lung Cancer Product Overview
Hensify – Lung Cancer Clinical Trial
Hensify – Prostate Cancer
Hensify – Prostate Cancer Product Overview
Hensify – Prostate Cancer Clinical Trial
Hensify – Rectal Cancer
Hensify – Rectal Cancer Product Overview
Hensify – Rectal Cancer Clinical Trial
Hensify – Soft Tissue Sarcoma
Hensify – Soft Tissue Sarcoma Product Overview
Hensify – Thoracic (Esophageal) Cancer
Hensify – Thoracic (Esophageal) Cancer Product Overview
NanoMag
NanoMag Product Overview
NanoPDT
NanoPDT Product Overview
Nanobiotix SA – Key Competitors
Nanobiotix SA – Key Employees
Nanobiotix SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nanobiotix SA, Recent Developments
Oct 23, 2020: Nanobiotix announces third quarter 2020 revenue
Feb 28, 2020: Nanobiotix 2019 Q4 and annual revenues
Jan 07, 2020: NANOBIOTIX announces plan for global phase III Head and Neck Cancer registration trial along with overall development update
Dec 16, 2019: NANOBIOTIX receives the 2019 Prix Galien award for first-in-class HENSIFY
Nov 12, 2019: NANOBIOTIX announces new results from pre-clinical immuno-oncology study at SITC 2019
Oct 25, 2019: NANOBIOTIX announces third quarter 2019 revenue
Sep 04, 2019: Nanobiotix announces half-year financial statements as of June 30, 2019
Jul 19, 2019: Nanobiotix announces second quarter 2019 revenue
Jul 01, 2019: NANOBIOTIX announces new organizational structure as the company enters its next stage after first European market approval
Jul 01, 2019: Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
Nanobiotix SA Pipeline Products and Ongoing Clinical Trials Overview
Nanobiotix SA Pipeline Products by Equipment Type
Nanobiotix SA Pipeline Products by Indication
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA, Key Facts
Nanobiotix SA, Major Products and Services
Nanobiotix SA Number of Pipeline Products by Development Stage
Nanobiotix SA Pipeline Products Summary by Development Stage
Nanobiotix SA Ongoing Clinical Trials by Trial Status
Nanobiotix SA Ongoing Clinical Trials Summary
Hensify - Breast Cancer - Product Status
Hensify - Breast Cancer - Product Description
Hensify - Gastrointestinal Cancer - Product Status
Hensify - Gastrointestinal Cancer - Product Description
Hensify - Genitourinary Cancer - Product Status
Hensify - Genitourinary Cancer - Product Description
Hensify - Glioblastoma - Product Status
Hensify - Glioblastoma - Product Description
Hensify - H&N & Lung Cancer - Product Status
Hensify - H&N & Lung Cancer - Product Description
Hensify - Head & Neck Cancer - Product Status
Hensify - Head & Neck Cancer - Product Description
Hensify - Head & Neck Cancer - A Phase Ib/II Study of PEP503 (Radioenhancer) with Radiotherapy in Combination with Concurrent Chemotherapy for Patients with Head and Neck Cancer
Hensify - Head & Neck Cancer - Overall Survival (OS)-based, Randomized, Event-driven Phase II/III Clinical Trial with Standard of Care Radiotherapy Combined with NBTXR3
Hensify - Head & Neck Cancer - PhI Study of NBTXR3 with Intensity Modulated Radiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Hensify - Liver Cancer - Product Status
Hensify - Liver Cancer - Product Description
Hensify - Liver Cancer - A Phase I-II Study of NBTXR3 Activated by Sterostatic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers
Hensify - Lung Cancer - Product Status
Hensify - Lung Cancer - Product Description
Hensify - Lung Cancer - Phase I Study of Reirradiation with NBTXR3 for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (NSCLC)
Hensify - Prostate Cancer - Product Status
Hensify - Prostate Cancer - Product Description
Hensify - Prostate Cancer - A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT with Brachytherapy in Patients with Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated with Androgen Deprivation
Hensify - Rectal Cancer - Product Status
Hensify - Rectal Cancer - Product Description
Hensify - Rectal Cancer - A Phase Ib/II Study of PEP503 (Radioenhancer) with Radiotherapy, in Combination with Concurrent Chemotherapy for Patients with Locally Advanced or Unresectable Rectal Cancer
Hensify - Soft Tissue Sarcoma - Product Status
Hensify - Soft Tissue Sarcoma - Product Description
Hensify - Thoracic (Esophageal) Cancer - Product Status
Hensify - Thoracic (Esophageal) Cancer - Product Description
NanoMag - Product Status
NanoMag - Product Description
NanoPDT - Product Status
NanoPDT - Product Description
Nanobiotix SA, Key Employees
Nanobiotix SA, Subsidiaries
Glossary